Tumor immunotherapy has been revolutionized by checkpoint inhibitors (CPIs) (1) targeting immune checkpoints such as the programmed cell death 1 protein (PD-1)/PD ligand (L)1 axis and cytotoxic T lymphocyte antigen 4 (CTLA-4). Here, PDCD1 is linked to neoplasm.